Product Press Release
HERCULES, CA – December 17, 2007 – Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics products, today announced the launch of Liquichek™ Diabetes Control, a liquid human whole blood-based third party control for monitoring the precision of Hemoglobin A1C tests on commonly used methods and instruments. Liquichek Diabetes Control provides an unbiased assessment, helping to detect changes in assay performance and improving the quality of test results.
The Unity™ Interlaboratory Program, with peer group comparison, is available for use with Liquichek Diabetes Control. Unity Real Time™, a complete QC data management software system designed to improve the effectiveness of quality control processes, is also available for use with Liquichek Diabetes Control.
About Bio-Rad
Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues of nearly $1.3 billion in 2006. For more information, visit www. bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.
For more information contact:
Tina Cuccia, Corporate Communications Manager
Bio-Rad Laboratories, Inc.
510-724-7000
Email: tina_cuccia@bio-rad.com